With a market capitalization (market cap) of $5.93B — a measure of how much the company is worth — Caris Life Sciences, Inc. is the 1297th most valuable company in Healthcare as of August 18, 2026. Shares trade at $20.97, down +3.05% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Visit websiteAs of August 18, 2026, Caris Life Sciences, Inc. (CAI) is worth $5.93B — this is its market capitalization, the total value of all its outstanding shares.
Caris Life Sciences, Inc.’s market cap is $5.93B, which ranks it #1297 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Caris Life Sciences, Inc. (CAI) shares trade at $20.97, down 3.05% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025